Why It Matters
WuXi AppTec Sales LLC, a U.S.-based subsidiary of a Chinese biotech firm, has switched lobbying representation after a federal designation threatened its federal contracts. Sander Lurie Consulting LLC registered the company as a new client on August 8, replacing DGA Group LLC, which terminated its engagement on July 1. The company is lobbying on health issues, marking a continuation of its federal advocacy efforts.
Over the past four quarters, WuXi AppTec Sales LLC has spent $2.14 million on lobbying. Alexander Lurie, founder of his consulting firm, previously served as Chief of Staff and Legislative Director for Sen. Debbie Stabenow (D-MI) from October 2007 to December 2007.
Broader Context
The BIOSECURE Act, enacted on December 18, 2025 as part of the FY2026 National Defense Authorization Act, does not designate specific companies as biotechnology companies of concern by name. Designation occurs through a forthcoming OMB list, which has not been published. China accounts for 94% of the key starting materials for amoxicillin used in America and 74% of heparin.
Between The Lines
A Senate hearing titled "Hearings To Examine Behind The Label, Focusing On Foreign Ownership And Control In America's Drug Supply Chain" was held on July 15, before the Senate Special Committee on Aging.
The Bottom Line
WuXi AppTec's shift to a new lobbying firm reflects the regulatory pressure facing Chinese biotech firms under the BIOSECURE Act. The company continues to navigate federal restrictions on its U.S. operations while Congress examines the role of foreign ownership in America's pharmaceutical supply chain.
Spot something wrong? Report an issue with this article